Literature DB >> 19175379

Unilateral RLS with predominantly ipsilateral PLMS and variable response to dopaminergic drugs: a variant of idiopathic RLS?

P O Valko1, M M Siccoli, C L Bassetti.   

Abstract

BACKGROUND: Restless legs syndrome (RLS) is characterized by sensorimotor symptoms that usually are localized in both legs, but may present considerable asymmetry. Patients with strictly and persisting unilateral manifestations have not yet been reported.
METHODS: We describe the clinical and electrophysiological characteristics of three RLS patients with unilateral symptoms.
RESULTS: All essential RLS criteria were fulfilled in each patient. Neuroimaging and electrophysiological studies did not reveal structural lesions. All patients showed a predominance of periodic limb movements in sleep (PLMS) ipsilaterally to the RLS symptoms. Treatment response to dopaminergic drugs was favourable only in one patient. CONTROLS: Our observations suggest the existence of unilateral RLS with predominantly ipsilateral PLMS as a (so-far unrecognized) variant of RLS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19175379     DOI: 10.1111/j.1468-1331.2008.02526.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  3 in total

1.  Depth and Distribution of Symptoms in Restless Legs Syndrome/ Willis-Ekbom Disease.

Authors:  Paul Yeh; William G Ondo; Daniel L Picchietti; J Steven Poceta; Richard P Allen; Charles R Davies; Lily Wang; Yaping Shi; Kanika Bagai; Arthur S Walters
Journal:  J Clin Sleep Med       Date:  2016-12-15       Impact factor: 4.062

2.  Repetitive Arm Movements During Sleep: A Polysomnographic Assessment.

Authors:  Mohammad Torabi-Nami; Samrad Mehrabi; Sabri Derman
Journal:  Basic Clin Neurosci       Date:  2016-07

3.  Restless abdomen: a spectrum or a phenotype variant of restless legs syndrome?

Authors:  Xi-Xi Wang; Xiao-Ying Zhu; Zan Wang; Jian-Wei Dong; William G Ondo; Yun-Cheng Wu
Journal:  BMC Neurol       Date:  2020-08-12       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.